**Question:** If a diabetic patient being treated with an oral hypoglycemic agent, develops dilutional hyponatremia, which one of the following could be responsible for this effect -

A. Diuretics
B. Thiazide diuretics
C. Angiotensin-converting enzyme (ACE) inhibitors
D. Angiotensin II receptor blockers (ARBs)

**Correct Answer:** D. Angiotensin II receptor blockers (ARBs)

**Core Concept:**

Dilutional hyponatremia is a condition characterized by a decrease in blood sodium levels due to excessive water intake or increased water loss in the body. In the context of a diabetic patient on oral hypoglycemic agents, the main concern is the development of hyponatremia, particularly when using medications that can enhance water retention or increase water permeability in the kidneys.

**Why the Correct Answer is Right:**

ARBs are a class of drugs used in the management of hypertension and diabetic nephropathy. They are angiotensin II receptor antagonists, which means they block the effects of angiotensin II, a hormone that contributes to vasoconstriction and aldosterone secretion, leading to increased sodium and water retention. In such a scenario, the patient on ARBs will tend to develop dilutional hyponatremia due to increased water loss in the body.

**Why Each Wrong Option is Incorrect:**

A. Diuretics: These drugs are designed to increase urine production, leading to water loss and subsequently, hyponatremia. However, they do not directly affect the renin-angiotensin-aldosterone system like ARBs do, which makes them less likely to cause dilutional hyponatremia.

B. Thiazide diuretics: These are also diuretics that increase urine production, leading to water loss and hyponatremia. However, they primarily act on the distal convoluted tubule in the kidneys, affecting sodium reabsorption and leading to hyponatremia, rather than dilutional hyponatremia.

C. Angiotensin-converting enzyme inhibitors (ACEIs): These drugs are another group of medications used in hypertension and diabetic nephropathy management. ACEIs work differently from ARBs, by inhibiting the conversion of angiotensin I to angiotensin II, which results in reduced aldosterone secretion, leading to increased sodium and water retention. Unlike ARBs, ACEIs do not directly cause dilutional hyponatremia.

**Clinical Pearl:**

Diabetic patients are susceptible to hypo- and hypernatremia due to the underlying disease state and medications used to manage it. Therefore, it is crucial for healthcare providers to be aware of potential drug interactions and side effects in these patients, including hyponatremia caused by medications like ARBs. Monitoring electrolyte levels in these patients is essential to identify and address these complications promptly.